Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Merck suspends enrollment of MK-0457 trials

Vertex (VRTX) said partner MRK suspended enrollment in trials of MK-0457 (VX-680) after QTc prolongation was observed in one patient in

Read the full 218 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE